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論文の内容の要旨 
Abstract of thesis 
（目的 Purpose） 
Myocardial infarction (MI) is one of the leading cause of death worldwide. The purpose of this study is to 
clarify the roles of rev-erb, a member of the nuclear receptor superfamily, in cardiac remodeling after MI and 
examine the effects of rev-erb agonist SR9009 on cardiac function and survival. 
 
（対象と方法 Materials and Methods） 
Wild-type C57BL6 male mice (n=165) were used to perform sham operation or permanent ligation of the left 
anterior descending coronary artery to induce MI. The applicant examined the expression of rev-erb (rev-erb α and 
β) during the early phase of post-MI (up to 7 days) and the survival was evaluated at 14-day post-MI. SR9009 or 
vehicle was administered by intraperitoneal injection (100 mg/kg/day) 1 day before the surgery and four 
experimental groups (Sham + vehicle, Sham + SR9009, MI + vehicle, MI + SR9009) were prepared for the 
analyses. The effect of SR9009 on post-MI cardiac functions was evaluated by echocardiography, gene expression 
analyses by real-time PCR, protein expression analyses by Western blotting and immunofluorescence staining. 
Immune cell infiltration into the left ventricle (LV) was evaluated by flow cytometry.  
 
 （結果 Results） 
The applicant first established the time course of rev-erb expression during MI and showed that it decreased at 
post-MI day 7. She then showed that survival after MI was significantly improved by pre-treatment with SR9009. 
Specifically, LV ejection fraction was improved, and mRNA expression and plasma concentration of brain 
natriuretic peptide were significantly decreased. Moreover, the expression levels of inflammatory-related genes 
such as Il6, Mcp1, Ly6g, Cd11b and matrix metalloproteinase-9 (MMP-9) protein and gene expression, as well as 
signaling molecules, including phosphorylated (p-)NF-kB p65, p-Erk, and p-p38 were significantly lower in 
SR9009-treated MI group than vehicle-treated MI group. Finally, the applicant showed that infiltrations of 
neutrophils and proinflammatory M1 macrophages into the infarct and border zone during the acute phase were 
significantly suppressed by SR9009.  
 
（考察 Discussion） 
1) The applicant suggested that SR9009 improved LV function and survival by suppressing the production of 
inflammatory cytokines and MMP-9, as well as infiltration of inflammatory cells into the infarcted and border zone 
during the acute phase of MI. There was no apparent toxicity of SR9009 in the current study which was consistent 
with the precious report.  
2) The applicant suggested that the mechanism of rev-erb was not only through the direct binding to the rev-erb α 
binding motif on the inflammatory cytokine genes but also through suppression of the NF-kB activity, ERK, and 
p38 signaling pathways.  
3) Although SR9009 showed a significant improvement of LV functions, collagen deposition appeared unaffected 
by SR9009 at 7-day post-MI. Further analysis is required for the evaluation of SR9009 on collagen deposition in 
chronic phase of post-MI. 
4) Pharmacological activation of rev-erb during acute phase of post-MI may offer an effective strategy to mitigate 
vicious cycle of inflammatory amplification, adverse LV remodeling and cardiac rupture.  
 
 
審査の結果の要旨 
 Abstract of assessment result 
 
（批評 General Comments） 
The applicant presented the novel finding on the temporal expression pattern of rev-erb α and β during early 
phase of MI.   Based on these findings, the applicant demonstrated that pre-treatment of SR9009 prior to induction 
of MI improved survival of animals and suppressed inflammatory cell infiltration into infarcted and border zone of 
LV. She provided the evidence that SR9009, an agonist of rev-erb, was beneficial to suppress acute phase of events 
after MI, such as inflammatory cytokine production, inflammatory cell infiltration and adverse remodeling caused 
by MMP-9. These findings are novel and provide a basis for the new therapeutic strategy for MI.   
 
（最終試験の結果 Assessment） 
The final examination committee conducted a meeting as a final examination on January 16, 2018. The 
applicant provided an overview of dissertation, addressed questions and comments raised during Q&A session. All 
of the committee members reached a final decision that the applicant has passed the final examination. 
 
（結論 Conclusion） 
Therefore, the final examination committee approved that the applicant is qualified to be awarded Doctor of 
Philosophy in Medical Sciences. 
 
